Pathol Oncol Res 2006,12(1):34–40.PubMedCrossRef 23. Stemler M, Weimer T, Tu ZX, Wan DF, Levrero M, Jung C, Pape GR, Will H: Mapping of B-cell epitopes of the human hepatitis B virus X protein. J Virol 1990,64(6):2802–2809.PubMed 24. Glebe D, Urban S: Viral

and TH-302 purchase cellular determinants involved in hepadnaviral entry. World J Gastroenterol 2007,13(1):22–38.PubMed 25. Locarnini S, McMillan J, Bartholomeusz A: The hepatitis B virus and common mutants. Semin Liver Dis 2003,23(1):5–20.PubMedCrossRef 26. Winters MA, Coolley KL, Cheng P, Girard YA, Hamdan H, Kovari LC, Merigan TC: Genotypic, phenotypic, and modeling studies of a deletion selleck in the beta3-beta4 region of the human immunodeficiency virus type 1 reverse transcriptase gene that is check details associated with resistance to nucleoside reverse transcriptase inhibitors. J Virol 2000,74(22):10707–10713.PubMedCrossRef 27. Cho SW, Hahm KB, Kim JH: Reversion from precore/core promoter

mutants to wild-type hepatitis B virus during the course of lamivudine therapy. Hepatology 2000,32(5):1163–1169.PubMedCrossRef 28. Ohkawa K, Takehara T, Kato M, Deguchi M, Kagita M, Hikita H, Sasakawa A, Kohga K, Uemura A, Sakamori R, et al.: Supportive role played by precore and preS2 genomic changes in the establishment of lamivudine-resistant hepatitis B virus. J Infect Dis 2008,198(8):1150–1158.PubMedCrossRef 29. Kondo Y, Asabe S, Kobayashi K, Shiina M, Niitsuma H, Ueno Y, Kobayashi T, Shimosegawa T: Recovery of functional cytotoxic T lymphocytes during lamivudine therapy by acquiring multi-specificity. J Med Virol 2004,74(3):425–433.PubMedCrossRef 30. Menne S, Tennant BC, Gerin JL, Cote PJ: Chemoimmunotherapy of chronic hepatitis B virus infection in the woodchuck model overcomes immunologic tolerance and restores T-cell responses to pre-S and S regions of the viral envelope protein. J Virol

2007,81(19):10614–10624.PubMedCrossRef 31. Park JH, Lee MK, Kim HS, Kim KL, Cho EW: Targeted destruction of the polymerized human serum albumin binding site within the preS2 region of the HBV surface antigen while retaining full immunogenicity for this epitope. J Viral Hepat 2003,10(1):70–79.PubMedCrossRef 32. Minami M, Okanoue T, Nakajima E, Yasui K, Kagawa K, Kashima K: Significance of pre-S region-defective hepatitis B virus that emerged during exacerbation of chronic type eltoprazine B hepatitis. Hepatology 1993,17(4):558–563.PubMedCrossRef 33. Chinese Society of Hepatology and Chinese Society of Infectious Diseases, Chinese Medical Association: Guideline on prevention and treatment of chronic hepatitis B in China (2010). Chin J Front Med Sci 2011,3(1):16. 34. Gunther S, Li BC, Miska S, Kruger DH, Meisel H, Will H: A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients. J Virol 1995,69(9):5437–5444.PubMed 35.